HO-1 overexpression has been reported in several cases/types of human malignancies. Unfortunately, poor clinical outcomes are reported in most of these cases, and the inhibition of HO-1 is considered a valuable and proven anticancer approach. To identify novel hit compounds suitable as HO-1 inhibitors, we report here a fragment-based approach where ligand joining experiments were used. The two most important parts of the classical structure of the HO-1 inhibitors were used as a starting point, and 1000 novel compounds were generated and then virtually evaluated by structure and ligand-based approaches. The joining experiments led us to a novel series of indole-based compounds. A synthetic pathway for eight selected molecules was designed, and the compounds were synthesized. The biological activity revealed that some molecules reach the micromolar activity, whereas molecule 4d inhibits the HO-1 with an IC50 of 1.03 μM. This study suggested that our joining approach was successful, and a novel hit compound was generated. These results are ongoing for further development.
HO-1过度表达已被报道在多种人类恶性肿瘤中。不幸的是,在大多数这些情况下,报道了糟糕的临床结果,因此HO-1的抑制被认为是一种有价值且经过验证的抗癌方法。为了寻找适合作为HO-1抑制剂的新型化合物,我们在这里报告了一种基于片段的方法,其中使用了配体连接实验。将HO-1抑制剂的经典结构的两个最重要的部分作为起点,生成了1000种新型化合物,并通过结构和配体基础方法进行了虚拟评估。连接实验使我们得到了一系列新型的吲哚基化合物。设计了八种选择分子的合成途径,并合成了这些化合物。生物活性显示,一些分子达到了微摩尔活性,而分子4d以1.03μM的IC50抑制了HO-1。这项研究表明,我们的连接方法是成功的,并生成了一种新型的命中化合物。这些结果正在进行进一步的开发。